Clinical Trials Browser

Phase 1/2 × Epirubicin × Gastrointestinal × Clear all

NCT00130936 2016-02-15

Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates

Phase 1/2 Terminated

Gastrointestinal

Esophageal Neoplasms, Neoplasms, Stomach Neoplasms

NCT00719550 2013-12-05

AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer

Phase 1/2 Completed

Gastrointestinal

Esophageal Neoplasms, Neoplasm Metastasis, Stomach Neoplasms

NCT00057980 2012-06-11

Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma

Phase 1/2 Completed

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT00021047 2012-03-08

Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor

Phase 1/2 Completed

CNSGastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Bile Duct Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Esthesioneuroblastoma, Olfactory